AstraZeneca PLC (AZN) - Total Liabilities
Based on the latest financial reports, AstraZeneca PLC (AZN) has total liabilities worth GBX65.36 Billion GBX (≈ $7.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AZN cash flow metrics to assess how effectively this company generates cash.
AstraZeneca PLC - Total Liabilities Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's total liabilities have evolved over time, based on quarterly financial data. Check AstraZeneca PLC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
AstraZeneca PLC Competitors by Total Liabilities
The table below lists competitors of AstraZeneca PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiayou International Logistics Co Ltd
SHG:603871
|
China | CN¥2.07 Billion |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082
|
China | CN¥1.78 Billion |
|
Test Research Inc
TW:3030
|
Taiwan | NT$2.55 Billion |
|
REN - Redes Energéticas Nacionais SGPS S.A
LS:RENE
|
Portugal | €3.74 Billion |
|
Wankai New Materials Co. Ltd.
SHE:301216
|
China | CN¥12.51 Billion |
|
Fibra Danhos
MX:DANHOS13
|
Mexico | MX$12.14 Billion |
|
Cetc Potevio Science&Technology Co Ltd
SHE:002544
|
China | CN¥5.55 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down AstraZeneca PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AstraZeneca PLC (AZN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AstraZeneca PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AstraZeneca PLC (1990–2025)
The table below shows the annual total liabilities of AstraZeneca PLC from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX65.36 Billion ≈ $7.95 Million |
+3.47% |
| 2024-12-31 | GBX63.16 Billion ≈ $7.69 Million |
+1.95% |
| 2023-12-31 | GBX61.95 Billion ≈ $7.54 Million |
+4.25% |
| 2022-12-31 | GBX59.42 Billion ≈ $7.23 Million |
-10.07% |
| 2021-12-31 | GBX66.08 Billion ≈ $8.04 Million |
+29.33% |
| 2020-12-31 | GBX51.09 Billion ≈ $6.22 Million |
+9.21% |
| 2019-12-31 | GBX46.78 Billion ≈ $5.69 Million |
+0.37% |
| 2018-12-31 | GBX46.61 Billion ≈ $5.67 Million |
-0.22% |
| 2017-12-31 | GBX46.71 Billion ≈ $5.68 Million |
+1.86% |
| 2016-12-31 | GBX45.86 Billion ≈ $5.58 Million |
+10.19% |
| 2015-12-31 | GBX41.62 Billion ≈ $5.06 Million |
+6.84% |
| 2014-12-31 | GBX38.95 Billion ≈ $4.74 Million |
+19.31% |
| 2013-12-31 | GBX32.65 Billion ≈ $3.97 Million |
+10.36% |
| 2012-12-31 | GBX29.58 Billion ≈ $3.60 Million |
+0.76% |
| 2011-12-31 | GBX29.36 Billion ≈ $3.57 Million |
-10.27% |
| 2010-12-31 | GBX32.72 Billion ≈ $3.98 Million |
-4.05% |
| 2009-12-31 | GBX34.10 Billion ≈ $4.15 Million |
+10.39% |
| 2008-12-31 | GBX30.89 Billion ≈ $3.76 Million |
-6.51% |
| 2007-12-31 | GBX33.04 Billion ≈ $4.02 Million |
+127.62% |
| 2006-12-31 | GBX14.52 Billion ≈ $1.77 Million |
+30.20% |
| 2005-12-31 | GBX11.15 Billion ≈ $1.36 Million |
-0.05% |
| 2004-12-31 | GBX11.15 Billion ≈ $1.36 Million |
+8.13% |
| 2003-12-31 | GBX10.32 Billion ≈ $1.26 Million |
-0.38% |
| 2002-12-31 | GBX10.36 Billion ≈ $1.26 Million |
+16.78% |
| 2001-12-31 | GBX8.87 Billion ≈ $1.08 Million |
-0.34% |
| 2000-12-31 | GBX8.90 Billion ≈ $1.08 Million |
-6.04% |
| 1999-12-31 | GBX9.47 Billion ≈ $1.15 Million |
+26.33% |
| 1998-12-31 | GBX7.50 Billion ≈ $912.05K |
+60.91% |
| 1997-12-31 | GBX4.66 Billion ≈ $566.80K |
-4.95% |
| 1996-12-31 | GBX4.90 Billion ≈ $596.33K |
+1.40% |
| 1995-12-31 | GBX4.83 Billion ≈ $588.09K |
+5.23% |
| 1994-12-31 | GBX4.59 Billion ≈ $558.87K |
-9.94% |
| 1993-12-31 | GBX5.10 Billion ≈ $620.56K |
-15.25% |
| 1992-12-31 | GBX6.02 Billion ≈ $732.24K |
+10.52% |
| 1991-12-31 | GBX5.45 Billion ≈ $662.52K |
+0.49% |
| 1990-12-31 | GBX5.42 Billion ≈ $659.26K |
-- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more